ERAS vs VSTM
ERAS: Erasca is a precision oncology company dedicated to shutting down the RAS/MAPK pathway to effectively treat patients with cancer. VSTM: Verastem Oncology is a clinical-stage biopharmaceutical firm commercializing precision medicine for KRAS-mutated cancers and advancing a pipeline of novel RAS/MAPK pathway inhibitors.
Side-by-side fundamentals
| Metric | ERAS | VSTM | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $15.46 | $8.11 | |
| Market cap | $5.4B | $734M | |
| Net margin FY2025, SEC XBRL | n/a | -677.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -550.3% | |
| ROE FY2025, SEC XBRL | -38.3% | -366.2% | ERAS higher |
| ROA FY2025, SEC XBRL | -31.4% | -85.0% | ERAS higher |
| Debt / equity as of 2026-09-03 | 0.00 | 1.01 | ERAS lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +209.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +97.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.33 | 1.25 | |
| 1-year return as of 2026-10-08 close | +536.2% | -9.3% | ERAS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.